CELG-RI — BRISTOL MYERS SQUIBB CO
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 14272 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,201,000,000 | 8,168,000,000 | -5,064,000,000 | 2,456,000,000 | 90,038,000,000 | 10,209,000,000 | 71,533,000,000 |
| Dec 2024 | 11,892,000,000 | 8,935,000,000 | -5,638,000,000 | 1,211,000,000 | 92,603,000,000 | 10,346,000,000 | 76,215,000,000 |
| Dec 2023 | 10,966,000,000 | 8,460,000,000 | -4,614,000,000 | 1,928,000,000 | 95,159,000,000 | 11,464,000,000 | 65,674,000,000 |
| Dec 2022 | 11,218,000,000 | 8,865,000,000 | -4,492,000,000 | 1,606,000,000 | 96,820,000,000 | 9,123,000,000 | 65,702,000,000 |
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 45,006,000,000 | -29,857,000,000 | 8,025,000,000 | 92,603,000,000 | 76,215,000,000 | 16,388,000,000 | — |
| Dec 2023 | 46,159,000,000 | -30,659,000,000 | 6,327,000,000 | 95,159,000,000 | 65,674,000,000 | 29,485,000,000 | — |
| Dec 2022 | 46,385,000,000 | -31,661,000,000 | 6,994,000,000 | 96,820,000,000 | 65,702,000,000 | 31,118,000,000 | — |
| Dec 2021 | 42,518,000,000 | -46,958,000,000 | -9,015,000,000 | 109,314,000,000 | 73,308,000,000 | 36,006,000,000 | — |
| Dec 2020 | 26,145,000,000 | -17,031,000,000 | 3,439,000,000 | 118,481,000,000 | 80,599,000,000 | 37,882,000,000 | — |
| Dec 2019 | 5,920,000,000 | — | 1,710,000,000 | 129,944,000,000 | 78,246,000,000 | 51,698,000,000 | — |
| Dec 2018 | 5,193,000,000 | — | 1,486,000,000 | 34,986,000,000 | 20,859,000,000 | 14,127,000,000 | — |
| Dec 2017 | 4,929,000,000 | — | 1,574,000,000 | 33,551,000,000 | 21,704,000,000 | 11,847,000,000 | — |
| Dec 2016 | 4,391,000,000 | — | 1,195,000,000 | 33,707,000,000 | 17,360,000,000 | 16,347,000,000 | — |
| Dec 2015 | 4,041,000,000 | — | 1,186,000,000 | 31,748,000,000 | 17,324,000,000 | 14,424,000,000 | — |
TTM Snapshot
Revenues TTM
$45,277,000,000
NetIncome TTM
$7,201,000,000
OpCashFlow TTM
$0
Assets (Latest)
$90,038,000,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
2026-09-28 11:29 · Yahoo
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
2026-09-28 10:44 · Yahoo
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-27 22:20 · Yahoo
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
2026-09-27 16:02 · Yahoo
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
2026-09-27 09:50 · Yahoo
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
2026-09-26 01:25 · Yahoo
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
2026-09-25 17:03 · Yahoo
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
2026-09-25 14:00 · Yahoo
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
2026-09-24 22:41 · Yahoo
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
2026-09-24 22:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.